Unlock the benefits
of DILAPAN-S

• Time savings of up to 2.4 hours per induction
• Minimal complications, eliminating the need for additional CTG monitoring
• Outpatient use with a low incidence of early admissions
• Predictability that allows for efficient labour ward scheduling

Women undergoing DILAPAN-S cervical ripening typically require minimal attention from hospital staff, allowing them to allocate their care to other patients. The gentle mode of action minimizes the risk of uterine hyperactivity and eliminates the need for repeated CTG monitoring or vaginal examinations. The unique hydrogel ensures consistency and predictability, achieving a cervical ripening success rate of approximately 80% over a 12–15 hour period.

• Achievable first-round cervical ripening success at around 80%
• Vaginal delivery rates up to approximately 80%
• VD24* rate on par with low-dose oral misoprostol

Clinical evidence suggests that about 4 out of 5 women may achieve successful ripening with the first series of DILAPAN-S. In comparison to prostaglandins, DILAPAN-S provides a comparable vaginal delivery rate, including delivery within 24 hours*, while offering a better safety profile and enhanced maternal satisfaction.


The data indicate that the way DILAPAN-S is used and the entire IOL clinical protocol may impact the outcomes reached.

*VD24 rate — vaginal delivery rate within 24 hours

• Risk of uterine tachysystole minimised
• Significantly reduced need for analgesia
• No serious adverse maternal or neonatal outcomes

DILAPAN-S non-pharmacological cervical ripening can help manage the issue of frequent uterine tachysystole and the risk of hyperstimulation. A large randomised clinical trial (RCT SOLVE) found that DILAPAN-S may significantly reduce the need for analgesics (particularly strong opioids) compared with the dinoprostone vaginal insert. The NICE guideline encourages discussion with women about the safety benefits and risks of mechanical versus pharmacological methods.

• Superior to PGEs and balloon catheter
• DILAPAN-S offers the possibility to relax, move, or sleep
• Less pain, significantly reduced need for analgesia

Across clinical trials that compared DILAPAN-S with dinoprostone, misoprostol, or balloon catheters, women reported superior satisfaction with the cervical ripening procedure using DILAPAN-S. The outcomes confirm DILAPAN-S as one of the gentlest cervical ripening agents, maintaining efficacy and providing additional safety benefits.

• Increase in vaginal delivery rate to 70% within 24 hours of admission
• Significant decrease in total length of hospital stay
• Only 2.4% return before the scheduled admission time
• Significant cost savings to the hospital

DILAPAN-S outpatient cervical ripening could offer efficacy and safety comparable to inpatient use, while enhancing maternal satisfaction. Its predictable and consistent action means a minimal number of women returning to the hospital before their scheduled time, aiding patient flow and scheduling efficiency.

• No gestational age limitations
• Recommended for outpatient cervical ripening
• Indicated for VBACs (Vaginal Birth after Caesarean)

Thanks to its non-pharmacological mode of action, DILAPAN-S can be used in almost all cases of induced labour, including those with high blood pressure (pre-eclampsia), gestational diabetes, systemic diseases, previous Caesarean sections, or premature rupture of membranes (PROM). The only contraindication for using DILAPAN-S is a clinically apparent genital tract infection.